![\"\"\/](\"https:\/\/www.europesays.com\/us\/wp-content\/uploads\/2025\/09\/1757088248045-430x241.jpg\")
<\/p>\n <\/p>\n
MD Anderson will have exclusive access to the new rimiducid formulation to be used with its inducible switch technologies. Credit: \u00a9 2025 The University of Texas MD Anderson Cancer Center.<\/p>\n
The University of Texas MD Anderson Cancer Center in the US and Phoenix SENOLYTIX have announced a worldwide cross-licensing agreement to advance the progress of inducible switch technologies for cell and gene therapy applications.<\/p>\n Phoenix will be supplied with the therapeutic agent, rimiducid, by MD Anderson and will receive assistance in obtaining regulatory clearance for a new formulation administered through intramuscular or subcutaneous injection, as an alternative to the conventional intravenous infusion.<\/p>\n \n\t\t\t\t\t\tCombine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.\n\t\t\t\t\t<\/p>\n In exchange, MD Anderson will have exclusive access to the new rimiducid formulation to be used with its switch technologies within its cell therapy platforms.<\/p>\n Rimiducid will initiate these technologies, which include the CaspaCIDe safety switch and the GoDCVaX, GoTCR, GoCAR-T and Dual Switch technologies that MD Anderson has acquired from Bellicum Pharmaceuticals.<\/p>\n Along with rimiducid, are employed as a safeguard to control the activation of cell and gene therapies.<\/p>\n The CaspaCIDe safety switch has been incorporated by the Institute for Cell Therapy Discovery & Innovation researchers at MD Anderson into a variety of cell therapy initiatives, notably in chimeric antigen receptor natural killer cell therapies.<\/p>\n The institution offered non-exclusive licences for the inducible switch technologies to biopharma companies and other academic entities.<\/p>\n David Spencer, co-founder and chief tech officer of Phoenix and Bellicum\u2019s scientific founder. originally developed the CaspaCIDe technology.<\/p>\n The ApoptiCIDe platform, representing an advancement of the original technology, has been developed by Phoenix to be compatible with the new formulation of rimiducid.<\/p>\n Phoenix has already employed this technology in its primary products, which are intended to selectively eliminate specific cell populations linked to ageing and obesity-related conditions.<\/p>\n In line with the latest agreement, MD Anderson and Phoenix have announced that they will set up a scientific advisory board to support the ongoing\u00a0development of these technologies for MD Anderson\u2019s cell therapy programmes.<\/p>\n Spencer stated: \u201cWe are excited about the broad medical opportunities presented by the dimerizer applications that would be enhanced with this new formulation of rimiducid.<\/p>\n \u201cThis reflects a potentially major advance that should further expand the adoption of cell and gene therapies.\u201d<\/p>\n Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by\u00a0Cytiva.<\/p>\n Editorial\u00a0content is independently produced and follows the\u00a0highest\u00a0standards<\/a>\u00a0of journalistic integrity. Topic sponsors are not involved in the creation of\u00a0editorial\u00a0content.<\/p>\n \n Sign up for our daily news round-up! Pharmaceutical Technology Excellence Awards – The Benefits of Entering<\/p>\n Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards<\/strong><\/a> celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don\u2019t miss your chance to stand out\u2014submit your entry today!<\/p>\n![\"\"](\"https:\/\/www.europesays.com\/us\/wp-content\/uploads\/2025\/09\/Cytiva-PT-image-1024x87.png\")
<\/a><\/p>\n![\"\"\/](\"https:\/\/www.pharmaceutical-technology.com\/wp-content\/themes\/goodlife-wp-B2B\/assets\/images\/GMS-logo.svg\"){kind=logo}
Discover B2B Marketing That Performs <\/p>\n
\n\t\t\t\t\t\t\tFind out more <\/a><\/p>\n![\"Email](\"https:\/\/www.pharmaceutical-technology.com\/wp-content\/themes\/goodlife-wp-B2B\/assets\/images\/newsletter-new.svg\")
<\/p>\n
\n Give your business an edge with our leading industry insights.\n <\/p>\n